The gut microbiota aids in uric acid metabolism
The gut microbiota has gained significant attention in recent years for its crucial involvement in the metabolism of uric acid, a biochemical process that has far-reaching consequences for an individual's overall health and well-being. In a meticulously designed scientific trial carried out by Bioyitech, the specific effects of Lactobacillus casei X11 were thoroughly investigated as a promising intervention for the condition known as hyperuricemia, which is characterized by elevated levels of uric acid in the blood. This research aims to deepen our understanding of the relationship between gut health and metabolic disorders, potentially paving the way for innovative therapeutic strategies.
**Experimental Methods**
A carefully structured randomized controlled trial was implemented, wherein specific pathogen-free mice were systematically allocated into four distinct groups: the control group (CON), the model group (MOD), the probiotic group (X11), and the active drug control group (ADC).
The methodology employed to establish the hyperuricemia (HUA) model is illustrated in Figure 1. The CON group was maintained on a standard diet supplemented with water, while the other groups were subjected to a high-purine diet, which comprised 400 g/kg of yeast extract, 20 g/kg of ribonucleic acid, and fructose water. To effectively induce HUA, the mice received intraperitoneal injections of potassium oxonate, dissolved in a 0.5% CMC-Na solution, at a dosage of 400 mg/kg over a duration of four weeks.
Following the successful establishment of the hyperuricemia model, treatment protocols commenced via gavage, with a dosage of 10 ml/kg body weight. The CON and MOD groups were treated with a saline solution of 0.85% NaCl, while the X11 group was administered a probiotic formulation containing 10^9 CFU/ml of Lactobacillus casei X11. The ADC group received 42 mg/kg of allopurinol (ALLO) as a comparative active treatment. Blood samples were meticulously collected from the retro-orbital venous plexus of the mice on days 7, 21, and 35 to monitor biochemical alterations. Furthermore, liver, kidney, and intestinal tissues were harvested and preserved at -80°C for subsequent analysis, ensuring the integrity of the samples for future investigations.
